BRILLIAN PHARMA
PharmaBRILLIAN PHARMA is a pharmaceutical company focused on Cardiovascular. Key products include SDAMLO.
BRILLIAN PHARMA's Key Drugs
BRILLIAN PHARMA's core commercial portfolio centers on SDAMLO, spanning Cardiovascular — its most strategically important drugs approved in the last 15 years.
BRILLIAN PHARMA's Recent FDA Approvals
BRILLIAN PHARMA secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.
BRILLIAN PHARMA's Therapeutic Areas
BRILLIAN PHARMA's approved drugs and pipeline span 1 therapeutic area, led by Cardiovascular, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
BRILLIAN PHARMA's Top Competitors
BRILLIAN PHARMA's closest competitors by therapeutic-area and drug-target overlap include Novartis, Merck, and Baxter. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
BRILLIAN PHARMA Pipeline Snapshot
BRILLIAN PHARMA has 1 active clinical program from ClinicalTrials.gov — 0 Phase 3, 0 Phase 2 and 1 Phase 1.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • SDAMLO leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Cardiovascular pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2025-07-24
- Latest
- 2026-05-08
- Applications
- 1